Key result
Irbesartan attenuated myocardial fibrosis and cardiac dysfunction in diabetic rats, and reduced NLRP3, ASC, Caspase-1 expressions, and IL-1β and IL-18 levels.
Why the study?
To observe the mechanism of myocardial injury in diabetic rats after irbesartan intervention and analyze the role of the NLRP3 inflammatory pathway.
Does irbesartan improve myocardial injury and cardiac function in diabetic rats?
Does irbesartan improve myocardial injury and cardiac function in diabetic rats?
Irbesartan may exert myocardial protection in diabetic rats by inhibiting the NLRP3/ASC/Caspase-1 inflammatory pathway.
Hypothesis-generating for irbesartan in diabetic cardiomyopathy via NLRP3; requires human validation before any clinical consideration.
To observe the mechanism of myocardial injury in diabetic rats after irbesartan intervention and analyze the role of nucleotide binding oligomerization domain-like receptor protein 3 (NLRP3) inflammatory pathway. The experiment was divided into four groups: normal control group (CON), high glucose and high caloric diet group (HC), diabetes group (DM) and diabetes+irbesartan group (DM+Ir). Compared with CON group, in HC group, triglyceride, total cholesterol and fasting blood glucose levels were increased; however, there was no significant difference of the cardiac function, the degree of myocardial fibrosis, NLRP3, ASC, Caspase-1 mRNA and protein expressions and the releasing of inflammatory factors interleukin (IL)-1β and IL-18. Compared with HC group, in DM group, triglyceride, total cholesterol, fasting blood glucose, IL-1β and IL-18 levels, NLRP3, ASC, Caspase-1 mRNA and protein expressions and the degree of myocardial fibrosis were increased, but the cardiac function was decreased. Compared with DM group, there were no changes in total cholesterol and fasting blood glucose, the degree of myocardial fibrosis cardiac function was attenuated, NLRP3, ASC, Caspase-1 expressions, IL-1β and IL-18 levels were reduced in DM+Ir group. The results suggested that irbesartan may exert myocardial protection by inhibiting the expression of the NLRP3/ASC/Caspase-1 pathway in diabetic rats.
No takes yet. Share an insight, caveat, or question.
Li et al. (2020) studied Myocardial injury in diabetes. Irbesartan vs. Diabetes group (DM) was evaluated on Myocardial fibrosis, cardiac function, and NLRP3/ASC/Caspase-1 pathway expression. Irbesartan attenuated myocardial fibrosis and cardiac dysfunction in diabetic rats, and reduced NLRP3, ASC, Caspase-1 expressions, and IL-1β and IL-18 levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: